Page 4 - ஆரோக்கியம் வாழ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆரோக்கியம் வாழ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆரோக்கியம் வாழ Today - Breaking & Trending Today

3rd COVID vaccine dose likely needed within 12 months, Pfizer CEO says


3rd COVID vaccine dose likely needed within 12 months, Pfizer CEO says
Updated Apr 15, 2021;
Those who receive a second dose of Pfizer’s coronavirus vaccine will likely need a third dose within 12 months, the company’s CEO said during a panel discussion hosted by CVS.
“A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual revaccination, but all of that needs to be confirmed. And again, the variants will play a key role,” Pfizer CEO Albert Bourla said during the event, called “CVS Health Live: Race to Vaccinate.” CVS posted video of the event on Facebook Thursday. ....

South Africa , United States , Stephane Bancel , David Kessler , Albert Bourla , Health Live , ஒன்றுபட்டது மாநிலங்களில் , டேவிட் கெஸ்லர் , ஆரோக்கியம் வாழ ,

Pfizer, Moderna Say Booster Shots Probably Needed


Pfizer, Moderna Say Booster Shots Probably Needed
By Ralph Ellis
April 16, 2021 People who’ve received both doses of the Pfizer-BioNTech or Moderna coronavirus vaccines will probably need a booster shot this year, top executives for those two pharmaceutical companies said this week.
Pfizer CEO Albert Bourla said people who’ve gotten both doses would likely need a third shot within 12 months and might need an annual shot thereafter.
There are vaccines . like polio that one dose is enough, there are vaccines like pneumococcal vaccine that one dose is enough for adults, and there are vaccines like flu that you need every year, Bourla said on a CVS Health Live event, “Race to Vaccinate.” The COVID virus looks more like the influenza virus than the polio virus. ....

United States , Alex Gorsky , Corinnem Le Goff , David Kessler , Albert Bourla , Health Live , Business Insider , House Select Subcommittee , ஒன்றுபட்டது மாநிலங்களில் , அலெக்ஸ் கோர்ஸ்கி , டேவிட் கெஸ்லர் , ஆரோக்கியம் வாழ , வணிக உள் ,

Third booster COVID-19 vaccine dose 'likely' needed: Pfizer CEO


Pfizer CEO says third COVID-19 vaccine dose likely needed
Pfizer CEO Albert Bourla said after receiving a booster shot targeting variants, annual vaccination against COVID-19 may be needed.
Author: Jack Norcross
Updated: 2:54 PM EDT April 15, 2021
The need for a third dose of the Pfizer vaccine between six and 12 months after a person is fully vaccinated will likely be needed, the CEO of Pfizer said in comments released Thursday.
A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual revaccination, Pfizer CEO Albert Bourla told CNBC s Bertha Coobs on CVS Health Live. ....

South Africa , Capitol Hill , District Of Columbia , United States , Albert Bourla , Bertha Coobs , Us Centers For Disease , Senate Finance Committee , Health Live , Disease Control , கேபிடல் மலை , மாவட்டம் ஆஃப் கொலம்பியா , ஒன்றுபட்டது மாநிலங்களில் , எங்களுக்கு மையங்கள் க்கு நோய் , செனட் நிதி குழு , ஆரோக்கியம் வாழ , நோய் கட்டுப்பாடு ,

Third Pfizer COVID-19 vaccine dose 'likely' needed within year, CEO says


Dr. Frita Fisher, certified in pediatrics, nephrology, and internal medicine weighs in on vaccine distribution on FOX News Live
Those who completed the two-dose regimen for Pfizer’s COVID-19vaccine will likely need a third shot within 12 months, CEO Albert Bourla said.
There is also a chance people will need to receive an annual COVID-19 vaccine thereafter, he said.
It is extremely important to suppress the pool of people that can be susceptible to the virus, Bourla told CNBC’s Bertha Coombs in a CVS Health Live event, Race to Vaccinate.  
Pfizer recently announced updated results indicating its vaccine was highly effective up to six months after the second dose, with findings stemming from over 12,000 participants in a late-stage trial. Findings included a 91.3% vaccine efficacy against COVID-19, and over 95% efficacy against severe disease. ....

South Africa , Albert Bourla , Bertha Coombs , Health Live , பெர்த்தா கும்பஸ் , ஆரோக்கியம் வாழ ,